Expert Interviews

Dr Sai-Hong Ou discusses the future of treatment for non-small cell lung cancer with EGFR exon 20 insertion mutations, highlighting the complexity of these mutations and the need for precision treatments.

In closing, experts share clinical pearls on open communication with patients, dose reduction strategies, and the relevance of treatment holidays for improving quality of life in patients with renal cell carcinoma.

Alexander I. Spira, MD, PhD, and Joshua K. Sabari, MD, discuss the prevalence of NRG1 fusions in pulmonary and gastrointestinal solid tumors and provide an overview of treatment practices.

Unmet needs in EGFR exon 20 insertion lung cancer, emphasizing the importance of early identification, selectivity against wild type EGFR, CNS activity, and mechanisms of resistance.

Panelists discuss the dosing schedule and patient education related to tivozanib, along with indications for potential treatment switch based on toxicity management and patient well-being.

Drs Misako Nagasaka, Sai-Hong Ou, Janellen Smith discuss the management of adverse events, such as infusion reactions and rash, associated with amivantamab treatment for patients with EGFR exon 20 insertion mutations.

It is important not to wash over the disparities in treatment access for renal cell carcinoma as merely another statistic and take action on guiding patients to treatment, says Solomon Woldu, MD.

African American and Hispanic patients with clear cell renal cell carcinoma may be less likely to receive treatment with immune checkpoint inhibitors than White patients, says Solomon Woldu, MD.

Cretostimogene grenadenorepvec’s efficacy compares favorably with the current nonsurgical standards of care in high-risk, Bacillus Calmette Guerin–unresponsive non-muscle invasive bladder cancer.

Artificial intelligence models may be “seamlessly incorporated” into clinical workflow in the management of prostate cancer, says Eric Li, MD.

Dr Dhakal outlines the FDA-approved CAR T-cell therapy products for patients with multiple myeloma who have undergone at least four prior lines of treatment, emphasizing a focus on individualized decision-making when selecting patients for CAR-T.

Joselle Cook, M.B.B.S., presents the case of a 62-year-old woman with high-risk multiple myeloma to the panel for discussion.

Dr Thomas Hutson outlines the diagnosis and staging of renal cell carcinoma, the surgical and non-surgical treatment options, and notes that while the majority of cases are potentially curable, 20-25% of patients present with or later develop metastatic disease.

Thomas Hutson, DO, PharmD, discusses renal cell carcinoma, including its epidemiology, risk factors, subtypes, and management approaches, in a dialogue with his clinical nurse, Kacie Ellis, RN, and his patient, Mr. Cesar Fuentes.

Robust genetic testing guidelines in the prostate cancer space must be supported by strong clinical research before they can be properly implemented, says William J. Catalona, MD.

Treatment with tisotumab vedotin may be a standard of care in second- or third-line recurrent or metastatic cervical cancer, says Brian Slomovitz, MD, MS, FACOG.

Comprehensive insights on quadruplet therapy regimens and the risk stratification process for patients with multiple myeloma.

A panel of experts on multiple myeloma discuss newly diagnosed patients and factors that determine transplant eligibility.

Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, offer key takeaways and conclude their discussion by offering advice for clinicians treating patients with NRG1 fusion–positive malignancies.

Drs Macarulla and Neuzillet discuss the role of zenocutuzumab in the treatment of patients with NRG1 fusion–positive solid tumors.